Bryan Townsend

Dec 19, 2024 | jdsupra.com | Bryan Townsend

Gurney-Goldman v. Goldman, C.A. No. 2023-1124-JTL (Del. Ch. July 12, 2024)Four siblings inherited equal 25 percent interests in the New York real estate empire of their late father. Two of the siblings (“Allan” and “Jane”) managed the business day to day. When Allan died, the 25 percent interest passed to his estate.

Nov 6, 2024 | jdsupra.com | Albert Carroll |Bryan Townsend

Stansell v. Rosensweig, C.A. No. 2023-0180-PAF (Del. Ch. June 12, 2024)The plaintiff was a stockholder of a company that provided online education resources. Some of the company's customers used its products to cheat on academic assignments and exams. In 2022, the company disseminated a notice of annual meeting and proxy statement. The meeting included elections of unopposed directors and ratification of the appointment of the company's independent auditor.

Nov 6, 2024 | jdsupra.com | Albert Carroll |Bryan Townsend

Green v. McClive, C.A. No. 2023-0139-MTZ (Del. Ch. June 3, 2024)The plaintiff filed claims against defendant McClive, alleging breach of contract, breach of fiduciary duty, and usurpation of corporate opportunities belonging to their Delaware LLC. In this letter decision, the Court of Chancery denied McClive’s motion to dismiss.

Jul 10, 2024 | jdsupra.com | Albert Carroll |Bryan Townsend

Soleimani v. Hakkak, C.A. No. 2023-0948-LWW (Del. Ch. Apr. 12, 2024)The defendants attempted to remove a manager-employee of several limited liability companies. The manager filed suit, and the parties moved for summary judgment regarding the removal’s effectiveness. The Court of Chancery determined that the relevant contracts’ unambiguous language required the defendants to first have made certain payments to the manager to remove him.

Jul 10, 2024 | jdsupra.com | Albert Carroll |Bryan Townsend

Himawan v. Cephalon, Inc., C.A. No. 2018-0075-SG (Del. Ch. Apr. 30, 2024)Stockholder representatives of an acquired corporation brought claims alleging that defendants had failed to use contractually-required commercially reasonable efforts to commercialize an acquired drug asset for a particular use.